Hepatic Encephalopathy (HE) Therapeutics - Global Market Insights and Sales Trends 2024

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.

The global Hepatic Encephalopathy (HE) Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hepatic Encephalopathy (HE) Therapeutics in various end use industries. The expanding demands from the Acute Liver Failure and Liver Cirrhosis, are propelling Hepatic Encephalopathy (HE) Therapeutics market. Lactulose, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Rifaximin segment is estimated at % CAGR for the next seven-year period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hepatic Encephalopathy (HE) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:
This report provides in-depth analysis of the global Hepatic Encephalopathy (HE) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Hepatic Encephalopathy (HE) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hepatic Encephalopathy (HE) Therapeutics sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Hepatic Encephalopathy (HE) Therapeutics covered in this report include ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt and Valeant, etc.

The global Hepatic Encephalopathy (HE) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hepatic Encephalopathy (HE) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

 1 Market Overview of Hepatic Encephalopathy (HE) Therapeutics
    1.1 Hepatic Encephalopathy (HE) Therapeutics Market Overview
        1.1.1 Hepatic Encephalopathy (HE) Therapeutics Product Scope
        1.1.2 Hepatic Encephalopathy (HE) Therapeutics Market Status and Outlook
    1.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
    1.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2018-2029)
    1.4 Global Hepatic Encephalopathy (HE) Therapeutics Historic Market Size by Region (2018-2023)
    1.5 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Forecast by Region (2024-2029)
    1.6 Key Regions, Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029)
        1.6.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029)
        1.6.2 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029)
        1.6.3 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029)
        1.6.4 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029)
        1.6.5 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029)

 2 Hepatic Encephalopathy (HE) Therapeutics Market by Type
    2.1 Introduction
        2.1.1 Lactulose
        2.1.2 Rifaximin
        2.1.3 Neomycin
        2.1.4 Probiotics
        2.1.5 Thiamine
    2.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
        2.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Historic Market Size by Type (2018-2023)
        2.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Type (2024-2029)
    2.3 Key Regions Market Size by Type
        2.3.1 North America Hepatic Encephalopathy (HE) Therapeutics Revenue Breakdown by Type (2018-2029)
        2.3.2 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue Breakdown by Type (2018-2029)
        2.3.3 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Revenue Breakdown by Type (2018-2029)
        2.3.4 Latin America Hepatic Encephalopathy (HE) Therapeutics Revenue Breakdown by Type (2018-2029)
        2.3.5 Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Revenue Breakdown by Type (2018-2029)

 3 Hepatic Encephalopathy (HE) Therapeutics Market Overview by Application
    3.1 Introduction
        3.1.1 Acute Liver Failure
        3.1.2 Liver Cirrhosis
    3.2 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
        3.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Historic Market Size by Application (2018-2023)
        3.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Application (2024-2029)
    3.3 Key Regions Market Size by Application
        3.3.1 North America Hepatic Encephalopathy (HE) Therapeutics Revenue Breakdown by Application (2018-2029)
        3.3.2 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue Breakdown by Application (2018-2029)
        3.3.3 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Revenue Breakdown by Application (2018-2029)
        3.3.4 Latin America Hepatic Encephalopathy (HE) Therapeutics Revenue Breakdown by Application (2018-2029)
        3.3.5 Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Revenue Breakdown by Application (2018-2029)

 4 Hepatic Encephalopathy (HE) Therapeutics Competition Analysis by Players
    4.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Players (2018-2023)
    4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatic Encephalopathy (HE) Therapeutics as of 2022)
    4.3 Date of Key Players Enter into Hepatic Encephalopathy (HE) Therapeutics Market
    4.4 Global Top Players Hepatic Encephalopathy (HE) Therapeutics Headquarters and Area Served
    4.5 Key Players Hepatic Encephalopathy (HE) Therapeutics Product Solution and Service
    4.6 Competitive Status
        4.6.1 Hepatic Encephalopathy (HE) Therapeutics Market Concentration Rate
        4.6.2 Mergers & Acquisitions, Expansion Plans

 5 Company (Top Players) Profiles
    5.1 ASKA Pharmaceutical
        5.1.1 ASKA Pharmaceutical Profile
        5.1.2 ASKA Pharmaceutical Main Business
        5.1.3 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Products, Services and Solutions
        5.1.4 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Revenue (US$ Million) & (2018-2023)
        5.1.5 ASKA Pharmaceutical Recent Developments
    5.2 COSMO PHARMACEUTICALS
        5.2.1 COSMO PHARMACEUTICALS Profile
        5.2.2 COSMO PHARMACEUTICALS Main Business
        5.2.3 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Products, Services and Solutions
        5.2.4 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Revenue (US$ Million) & (2018-2023)
        5.2.5 COSMO PHARMACEUTICALS Recent Developments
    5.3 Mallinckrodt
        5.3.1 Mallinckrodt Profile
        5.3.2 Mallinckrodt Main Business
        5.3.3 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Products, Services and Solutions
        5.3.4 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Revenue (US$ Million) & (2018-2023)
        5.3.5 Valeant Recent Developments
    5.4 Valeant
        5.4.1 Valeant Profile
        5.4.2 Valeant Main Business
        5.4.3 Valeant Hepatic Encephalopathy (HE) Therapeutics Products, Services and Solutions
        5.4.4 Valeant Hepatic Encephalopathy (HE) Therapeutics Revenue (US$ Million) & (2018-2023)
        5.4.5 Valeant Recent Developments

 6 North America
    6.1 North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2018-2029)
    6.2 U.S.
    6.3 Canada

 7 Europe
    7.1 Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2018-2029)
    7.2 Germany
    7.3 France
    7.4 U.K.
    7.5 Italy
    7.6 Russia
    7.7 Nordic Countries
    7.8 Rest of Europe

 8 Asia-Pacific
    8.1 Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2018-2029)
    8.2 China
    8.3 Japan
    8.4 South Korea
    8.5 Southeast Asia
    8.6 India
    8.7 Australia
    8.8 Rest of Asia-Pacific

 9 Latin America
    9.1 Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2018-2029)
    9.2 Mexico
    9.3 Brazil
    9.4 Rest of Latin America

 10 Middle East & Africa
    10.1 Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2018-2029)
    10.2 Turkey
    10.3 Saudi Arabia
    10.4 UAE
    10.5 Rest of Middle East & Africa

 11 Hepatic Encephalopathy (HE) Therapeutics Market Dynamics
    11.1 Hepatic Encephalopathy (HE) Therapeutics Industry Trends
    11.2 Hepatic Encephalopathy (HE) Therapeutics Market Drivers
    11.3 Hepatic Encephalopathy (HE) Therapeutics Market Challenges
    11.4 Hepatic Encephalopathy (HE) Therapeutics Market Restraints

 12 Research Finding /Conclusion

 13 Methodology and Data Source
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer

List of Tables
    Table 1. Global Market Hepatic Encephalopathy (HE) Therapeutics Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
    Table 2. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 3. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Share by Region (2018-2023)
    Table 4. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 5. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size Share by Region (2024-2029)
    Table 6. Global Hepatic Encephalopathy (HE) Therapeutics Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
    Table 7. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 8. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2018-2023)
    Table 9. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 10. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2024-2029)
    Table 11. North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2018-2023) & (US$ Million)
    Table 12. North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2024-2029) & (US$ Million)
    Table 13. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2018-2023) & (US$ Million)
    Table 14. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2024-2029) & (US$ Million)
    Table 15. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2018-2023) & (US$ Million)
    Table 16. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2024-2029) & (US$ Million)
    Table 17. Latin America Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2018-2023) & (US$ Million)
    Table 18. Latin America Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2024-2029) & (US$ Million)
    Table 19. Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2018-2023) & (US$ Million)
    Table 20. Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Revenue by Type (2024-2029) & (US$ Million)
    Table 21. Global Hepatic Encephalopathy (HE) Therapeutics Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
    Table 22. Global Hepatic Encephalopathy (HE) Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 23. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2018-2023)
    Table 24. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 25. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2024-2029)
    Table 26. North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2018-2023) & (US$ Million)
    Table 27. North America Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2024-2029) & (US$ Million)
    Table 28. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2018-2023) & (US$ Million)
    Table 29. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2024-2029) & (US$ Million)
    Table 30. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2018-2023) & (US$ Million)
    Table 31. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2024-2029) & (US$ Million)
    Table 32. Latin America Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2018-2023) & (US$ Million)
    Table 33. Latin America Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2024-2029) & (US$ Million)
    Table 34. Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2018-2023) & (US$ Million)
    Table 35. Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Revenue by Application (2024-2029) & (US$ Million)
    Table 36. Global Hepatic Encephalopathy (HE) Therapeutics Revenue (US$ Million) by Players (2018-2023)
    Table 37. Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Players (2018-2023)
    Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatic Encephalopathy (HE) Therapeutics as of 2022)
    Table 39. Date of Key Players Enter into Hepatic Encephalopathy (HE) Therapeutics Market
    Table 40. Global Hepatic Encephalopathy (HE) Therapeutics Key Players Headquarters and Area Served
    Table 41. Hepatic Encephalopathy (HE) Therapeutics Product Solution and Service
    Table 42. Global Hepatic Encephalopathy (HE) Therapeutics Players Market Concentration Ratio (CR5 and HHI)
    Table 43. Mergers & Acquisitions, Expansion Plans
    Table 44. ASKA Pharmaceutical Basic Information List
    Table 45. ASKA Pharmaceutical Description and Business Overview
    Table 46. ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Products, Services and Solutions
    Table 47. Revenue (US$ Million) in Hepatic Encephalopathy (HE) Therapeutics Business of ASKA Pharmaceutical (2018-2023)
    Table 48. ASKA Pharmaceutical Recent Developments
    Table 49. COSMO PHARMACEUTICALS Basic Information List
    Table 50. COSMO PHARMACEUTICALS Description and Business Overview
    Table 51. COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Products, Services and Solutions
    Table 52. Revenue (US$ Million) in Hepatic Encephalopathy (HE) Therapeutics Business of COSMO PHARMACEUTICALS (2018-2023)
    Table 53. COSMO PHARMACEUTICALS Recent Developments
    Table 54. Mallinckrodt Basic Information List
    Table 55. Mallinckrodt Description and Business Overview
    Table 56. Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Products, Services and Solutions
    Table 57. Revenue (US$ Million) in Hepatic Encephalopathy (HE) Therapeutics Business of Mallinckrodt (2018-2023)
    Table 58. Mallinckrodt Recent Developments
    Table 59. Valeant Basic Information List
    Table 60. Valeant Description and Business Overview
    Table 61. Valeant Hepatic Encephalopathy (HE) Therapeutics Products, Services and Solutions
    Table 62. Revenue (US$ Million) in Hepatic Encephalopathy (HE) Therapeutics Business of Valeant (2018-2023)
    Table 63. Valeant Recent Developments
    Table 64. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 65. North America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 66. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 67. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 68. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 69. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 70. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size by Region (2024-2029) & (US$ Million)
    Table 71. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Share by Region (2018-2023)
    Table 72. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Share by Region (2024-2029)
    Table 73. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 74. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 75. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 76. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 77. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 78. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 79. Hepatic Encephalopathy (HE) Therapeutics Market Trends
    Table 80. Hepatic Encephalopathy (HE) Therapeutics Market Drivers
    Table 81. Hepatic Encephalopathy (HE) Therapeutics Market Challenges
    Table 82. Hepatic Encephalopathy (HE) Therapeutics Market Restraints
    Table 83. Research Programs/Design for This Report
    Table 84. Key Data Information from Secondary Sources
    Table 85. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Year-over-Year 2018-2029 & (US$ Million)
    Figure 2. Global Hepatic Encephalopathy (HE) Therapeutics Market Size (US$ Million), 2018 VS 2022 VS 2029
    Figure 3. Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Regions: 2022 VS 2029
    Figure 4. Global Hepatic Encephalopathy (HE) Therapeutics Forecasted Market Size Share by Region (2024-2029)
    Figure 5. North America Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 6. Europe Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 7. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 8. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 9. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 10. Product Picture of Lactulose
    Figure 11. Global Lactulose Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 12. Product Picture of Rifaximin
    Figure 13. Global Rifaximin Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 14. Product Picture of Neomycin
    Figure 15. Global Neomycin Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 16. Product Picture of Probiotics
    Figure 17. Global Probiotics Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 18. Product Picture of Thiamine
    Figure 19. Global Thiamine Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 20. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Share by Type:  2022 & 2029
    Figure 21. North America Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2018-2029)
    Figure 22. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2018-2029)
    Figure 23. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2018-2029)
    Figure 24. Latin America Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2018-2029)
    Figure 25. Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type (2018-2029)
    Figure 26. Acute Liver Failure Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 27. Liver Cirrhosis Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 28. Global Hepatic Encephalopathy (HE) Therapeutics Market Size Share by Application: 2022 & 2029
    Figure 29. North America Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2018-2029)
    Figure 30. Europe Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2018-2029)
    Figure 31. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2018-2029)
    Figure 32. Latin America Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2018-2029)
    Figure 33. Middle East and Africa Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Application (2018-2029)
    Figure 34. Hepatic Encephalopathy (HE) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 35. Global Top 5 and Top 10 Players Hepatic Encephalopathy (HE) Therapeutics Market Share in 2022
    Figure 36. North America Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2018-2029)
    Figure 37. U.S. Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 38. Canada Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 39. Germany Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 40. France Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 41. U.K. Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 42. Italy Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 43. Russia Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 44. Nordic Countries Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 45. Asia-Pacific Hepatic Encephalopathy (HE) Therapeutics Market Share by Region (2018-2029)
    Figure 46. China Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 47. Japan Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 48. South Korea Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 49. Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 50. India Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 51. Australia Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 52. Latin America Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2018-2029)
    Figure 53. Mexico Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 54. Brazil Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 55. Middle East & Africa Hepatic Encephalopathy (HE) Therapeutics Market Share by Country (2018-2029)
    Figure 56. Turkey Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 57. Saudi Arabia Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 58. UAE Hepatic Encephalopathy (HE) Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 59. Bottom-up and Top-down Approaches for This Report

HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.

The global Hepatic Encephalopathy (HE) Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hepatic Encephalopathy (HE) Therapeutics in various end use industries. The expanding demands from the Acute Liver Failure and Liver Cirrhosis, are propelling Hepatic Encephalopathy (HE) Therapeutics market. Lactulose, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Rifaximin segment is estimated at % CAGR for the next seven-year period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hepatic Encephalopathy (HE) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:
This report provides in-depth analysis of the global Hepatic Encephalopathy (HE) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Hepatic Encephalopathy (HE) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hepatic Encephalopathy (HE) Therapeutics sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Hepatic Encephalopathy (HE) Therapeutics covered in this report include ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt and Valeant, etc.

The global Hepatic Encephalopathy (HE) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hepatic Encephalopathy (HE) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion